Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    Biological and chemical terrorism: Recognition and management
    Thomas P. Noeller, MD
    Cleveland Clinic Journal of Medicine December 2001, 68 (12) 1001-1016;

    Future terrorist attacks might involve a variety of chemical or biological agents, including nerve agents, blistering agents, hydrogen cyanide, ricin, anthrax, smallpox, plague, and botulinum toxin. Physicians are on the front line.

  • When should central venous catheters be changed in the intensive care unit? Should there be a rigid time-based protocol for doing so?
    You have access
    When should central venous catheters be changed in the intensive care unit? Should there be a rigid time-based protocol for doing so?
    Stephen A. Mette, MD
    Cleveland Clinic Journal of Medicine December 2001, 68 (12) 994-996;

    The decision is made case by case rather than on a time-based protocol. Proactive strategies can reduce the risk of infection.

  • You have access
    Cox - 2 Inhibitors and Cardiovascular Risk
    John Lipani, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 961-962;

    Unless a clear cause-and-effect relationship can be proved between COX-2 inhibitors and cardiovascular events, we should go on using these drugs.

  • You have access
    Cox - 2 Inhibitors and Cardiovascular Risk
    Brian F. Mandell, MD, PHD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 957-959;

    Even if we do not know with certainty whether COX-2 inhibitors increase the risk of cardiovascular events, we need to incorporate this concern into our practice.

  • How often are atrial septal defects associated with thromboembolism? When should they be looked for?
    You have access
    How often are atrial septal defects associated with thromboembolism? When should they be looked for?
    Wael A. Jaber, MD and Allan L. Klein, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 954-956;

    In the absence of other causative conditions, an atrial septal defect may be presumed to be the underlying cause of a stroke, especially in younger patients.

  • You have access
    Cox - 2 Inhibitors and Cardiovascular Risk
    Debabrata Mukherjee, MD, Steven E. Nissen, MD and Eric J. Topol, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 963-964;

    Our study had limitations, but we believe our hypothesis is plausible, our methods were valid, and our conclusions are sound.

  • You have access
    Recognizing and treating diabetic autonomic neuropathy
    Aaron I. Vinik, MD, PhD and Tomris Eras, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 928-944;

    Strict glycemic control can slow the onset of diabetic autonomic neuropathy and sometimes reverse it. Other treatments address specific symptoms.

  • You have access
    Chronic myelogenous leukemia: The news you have and haven’t heard
    Matt E. Kalaycio, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 913-926;

    One major advance in treating CML was widely publicized. Another, although equally important, was not.

  • You have access
    A 44-year-old man with a pruritic skin rash
    Raed Bargout, MD and Amit Malhotra, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 952-953;

    Questions and answers on the visible signs of diseases.

  • You have access
    COX-2 inhibitors: Balancing the hope, the hype, and the concern
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 899;

    When all is said and done, the choice rests with the individual prescribing physician.

Pages

  • Previous
  • Next
  • 1
  • …
  • 396
  • 397
  • 398
  • 399
  • 400
  • 401
  • 402
  • 403
  • 404
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire